by Madaline Spencer | May 12, 2026
Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses new follow-up data on KYV-101 treatment for patients with myasthenia gravis (MG). Generalized MG (gMG) is a chronic autoimmune neuromuscular disease...
by Madaline Spencer | May 11, 2026
Amol Sura, MD, Foster Center for Ocular Immunology, Dept of Ophthalmology, Duke University, Durham, North Carolina, discusses the diagnosis and management of plasminogen deficiency, a rare condition in which the eyes are first affected, but it manifests in mucous...
by Madaline Spencer | May 11, 2026
William W. Motley, MD, RAP-219 Program Leader at Rapport Therapeutics, discusses follow-up data of RAP-219 for the treatment of focal onset seizures. Focal onset seizures refer to abnormal neural activity in one brain area within one brain hemisphere...
by Madaline Spencer | May 8, 2026
Brian Moseley, MD, Senior Medical Director at UCB, discusses the GEMZ clinical trial of fenfluramine in patients with CDKL5 deficiency disorder (CDD). CDD is a rare genetic disorder characterized by difficult‑to‑control seizures and severe neuro‑developmental...
by Madaline Spencer | May 7, 2026
Colin Lake, Head of Digital Business Transformation Neurology at UCB, discusses CareCompass, an online tool for caregivers of patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). DS is the most severe of a group of conditions known as...
